Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
Holding JAZZ?
Track your performance easily
JAZZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$99.06 - $134.17
Previous CloseN/A
Volume75.28K
Average Volume (3M)562.54K
Market Cap
$7.41B
Enterprise Value$10.62B
Total Cash (Recent Filing)$425.96M
Total Debt (Recent Filing)$1.99B
Price to Earnings (P/E)17.7
Beta0.71
Next Earnings
Mar 04, 2025EPS Estimate
5.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.94
Shares Outstanding60,454,594
10 Day Avg. Volume489,610
30 Day Avg. Volume562,536
Standard Deviation0.08
R-Squared0.13
Alpha-0.00621
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.87
Price to Cash Flow (P/CF)4.70
P/FCF Ratio4.80
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue2.66
Enterprise Value/Gross Profit3.13
Enterprise Value/Ebitda11.51
Forecast
1Y Price Target
$179.36Price Target Upside46.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Jazz Pharmaceuticals News
PremiumCompany Announcements
Jazz Pharmaceuticals Announces CEO Bruce Cozadd’s Retirement Plan
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRecord 3Q $1,055M revenue reiterated with Xywav and Epidiolex beating consensus.
Patent ProtectionJAZZ has a handful of MOU patents for Clobazam DDI & more recently JAZZ filed another new patent on Epidiolex's DDI with everolimus, which can help extend the patent life to 2030+.
Product Launch And Market PotentialThe recent launch of Ziihera with a price close to estimates and its inclusion in NCCN guidelines reflects management's confidence in its success.
Bears Say
Legal IssuesThe setup could be trickier due to ongoing lawsuits, including an anti-trust case against AVDL.
Market CompetitionThe outlook for Xywav in narcolepsy and IH is challenged by the entry of generics and other competitors.
Oncology SegmentThe lowered oncology sales guidance suggests potential challenges in this segment.
---
Ownership Overview
3.26% Insiders
26.58% Mutual Funds
1.00% Other Institutional Investors
41.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $99.06 and its highest was $134.17 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $7.41B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 45 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported $6.61 earnings per share for the quarter, beating the consensus estimate of $5.498 by $1.112.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 5.8.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 60,454,594 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $6.61 in its last earnings report, beating expectations of $5.498. Following the earnings report the stock price went up 6.75%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Among the largest hedge funds holding Jazz Pharmaceuticals’s share is Polaris Capital Management LLC. It holds Jazz Pharmaceuticals’s shares valued at 145M.
---
Jazz Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$179.36 (46.27% Upside)
$179.36 (46.27% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 846.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.92%
12-Months-Change
Fundamentals
Return on Equity
12.09%
Trailing 12-Months
Asset Growth
9.39%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
---
JAZZ Company Deck
---
JAZZ Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected strong performance across Jazz Pharmaceuticals' commercial portfolio, particularly in neuroscience and oncology, with record sales and positive clinical trial results for Zepzelca. However, there were challenges with Rylaze revenue due to updated treatment protocols and a trial setback for Epidiolex in Japan. Overall, the positive financial results and growth prospects balanced out the highlighted challenges.Read More>---
JAZZ Stock 12 Month Forecast
Average Price Target
$179.36
▲(46.27% Upside)
Technical Analysis
Vertex Pharmaceuticals
―
Alkermes
―
BioMarin Pharmaceutical
―
Xencor
―
ACADIA Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering JAZZ
1 Year
1 Year Success Rate
18/26 ratings generated profit
1 Year Average Return
+5.81%
reiterated a buy rating last month
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +5.81% per trade.
---